CoreCap Advisors LLC Sells 44,466 Shares of Gilead Sciences, Inc. $GILD during the third quarter, marking a significant reduction in its equity exposure to the biopharmaceutical company according to recent regulatory filings. The investment firm lowered its position by 95.4%, retaining 2,158 shares valued at $322,000 as of its most recent SEC filing. This adjustment highlights a notable pullback by the firm while other institutional investors and corporate insiders navigate shifting positions across the market.
What Changed in Institutional Holdings
While CoreCap Advisors made a sharp downward adjustment to its portfolio, several other large institutional investors and hedge funds modified their stakes in Gilead Sciences, Inc. during the second quarter. Institutional investors and hedge funds overall own 83.67% of the company’s stock.
Notable institutional transactions include:
- Bank of Nova Scotia: Bought a new stake in Gilead Sciences in the second quarter valued at approximately $100,056,000.
- OMERS ADMINISTRATION Corp: Acquired a new stake in the second quarter worth $55,754,000.
- Groupe la Francaise: Increased its position by 30.9% in the second quarter, bringing its holdings to 49,627 shares worth $6,270,000.
- Baird Financial Group Inc.: Increased its position by 3.6% in the second quarter, owning 292,295 shares valued at $36,929,000.
- Headlands Technologies LLC: Bought a new position during the second quarter worth $6,251,000.
Insider Trading Activity
Alongside institutional realignments, corporate insiders have executed notable share sales under predefined trading rules. Director Jeffrey Bluestone sold 5,000 shares on Thursday, August 20th at an average price of $145.02, totaling $725,100.00 under a Rule 10b5-1 plan. Additionally, Chief Financial Officer Andrew D. Dickinson sold 3,000 shares on Tuesday, September 15th at an average price of $145.29, generating $435,870.00 under a similar Rule 10b5-1 plan.
Over the preceding quarter, company insiders sold a combined total of 105,000 shares valued at $14,940,540. Corporate insiders currently own 0.30% of Gilead Sciences stock.
Financial Performance and Market Position
Gilead Sciences stock opened at $150.43, operating within a 52-week range defined by a low of $114.02 and a high of $157.29. The company maintains a market capitalization of $186.53 billion, a P/E ratio of -56.34, and a beta of 0.31.
In its quarterly earnings report released on Monday, August 3rd, Gilead reported earnings per share (EPS) of ($6.75), beating consensus estimates of ($7.25) by $0.50. Quarterly revenue reached $7.80 billion, representing a 10.6% increase compared to the same period in the previous year. Furthermore, Gilead paid a quarterly dividend of $0.82 per share on Tuesday, September 29th, to shareholders of record as of Tuesday, September 15th.
Analyst Ratings and Price Targets
Wall Street analysts have provided a range of evaluations regarding Gilead Sciences’ market trajectory:
- Bank of America: Reiterated a ‘buy’ rating and set a $164.00 target price.
- Barclays: Decreased their price target from $155.00 to $145.00 and set an ‘equal weight’ rating on July 29th.
- Leerink Partners: Downgraded the stock from ‘outperform’ to ‘market perform’ and reduced their price objective from $146.00 to $127.00 on July 21st.
- HSBC: Raised its price objective from $155.00 to $175.00 and issued a ‘buy’ rating on September 10th.
- Truist Financial: Increased its price objective from $150.00 to $158.00 and maintained a ‘buy’ rating on October 7th.
Overall, twenty-three analysts have assigned a Buy rating while six have issued a Hold rating. This consensus forms a ‘Moderate Buy’ average rating alongside an average consensus price target of $159.33.
Business Implications and Sector Impact
The simultaneous reduction of stakes by firms like CoreCap Advisors alongside multi-million-dollar inflows from entities like the Bank of Nova Scotia and OMERS Administration illustrates the divergent strategies active within the biopharmaceutical sector. While institutional backing remains high at over 83%, individual portfolio adjustments and scheduled insider sales under Rule 10b5-1 plans provide ongoing data points for market watchers tracking corporate governance and valuation metrics.
Limitations
This report reflects publicly available regulatory filings, earnings disclosures, and analyst revisions as recorded during the specified periods. Financial metrics such as market capitalization, share prices, and analyst consensus targets are subject to continuous market fluctuations and may change following subsequent financial disclosures.